期刊文献+

乳腺癌免疫检查点及其抑制剂的研究进展

下载PDF
导出
摘要 乳腺癌已超过肺癌成为最常见的恶性肿瘤,且病死率居全部恶性肿瘤前五位。肿瘤可以激活与免疫稳态相关的负调节途径以及主动逃避免疫细胞的监测,因此免疫系统在肿瘤中的作用在过去未被重视。近年来肿瘤免疫疗法才成为研究热点。肿瘤免疫疗法通过重新启动并维持肿瘤-免疫循环,恢复机体正常的抗肿瘤免疫反应,而不仅限于针对单个致癌基因紊乱或肿瘤细胞的其他自主特征,因此,肿瘤免疫疗法可以产生抗肿瘤活性。在不同类型的肿瘤免疫疗法中,免疫检查点抑制剂的影响最为广泛。本文就乳腺癌相关经典免疫检查点和新型免疫检查点及其抑制剂的研究进展进行综述。
出处 《癌症进展》 2023年第5期481-485,516,共6页 Oncology Progress
  • 相关文献

参考文献1

二级参考文献49

  • 1Goldhirsch A, Wood WC, Coates AS, et al. Strategies for sub types-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011,22 (8):1736 -1747.
  • 2The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours [J]. Nature, 2012, 490 (7418) :61- 70.
  • 3Dunbier AK,Anderson H,Ghazoui Z, et al. Association between breast cancer subtypes and response to neoadjuvant anastrozole [J]. Steroids, 2011,76(8) :736-740.
  • 4Ellis M J, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition[J]. Nature,2012, 486(7403) :353-360.
  • 5Galimberti V,Botteri E,Chifu C,et al. Can we avoid axillary dis- section in the micrometastatic sentinel node in breast cancer? [J]. Breast Cancer Res Treat,2012,131(3) : 819-825.
  • 6Martelli G,Boracchi P,Ardoino I,et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial[J]. Ann Surg, 2012,256(6) : 920-924.
  • 7Goldhirsch A,Gelber RD,Piccart-Gebhart MJ,et al. 2 years ver- sus 1 year of adjuvant trastuzumab for HER-2 positive breast cancer (HERA) :an open-label, randomised controlled trial[J]. Lancet,2013,382(9897) :1021-1028.
  • 8Pivot X,Romieu G,Debled M,et al. 6 months versus 12 months of adjuvant trastuzumah for patients with HER-2-positive early breast cancer (PHARE):a randomised phase 3 trial[J]. Lancet Oncol, 2013,14 (8) : 741-748.
  • 9Davies C,Pan H, Godwin J, et al. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet,2013,381 (9869) :805-816.
  • 10Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER-2 status, and prognosis of patients with luminal B breast cancer[J]. J Natl Cancer Inst,2009,101(10) :736-750.

共引文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部